Pharmaceutical Research

, Volume 5, Issue 8, pp 528–532 | Cite as

Formulation of Vaccine Adjuvant Muramyldipeptides (MDP). 2. The Thermal Reactivity and pH of Maximum Stability of MDP Compounds in Aqueous Solution

  • Michael F. Powell
  • Linda C. Foster
  • Allyn R. Becker
  • William Lee


The degradation of muramyldipeptides (MDPs) in aqueous solution obeys the rate law kobs = kHH+ + ko + kHO-aHO- and the Arrhenius equation. For example, the rate constants for degradation of N-acetylmuramyl-L-threonyl-D-isoglutamine, 3, at 25°C are kH+ = 2.3 × 10−6M−1 sec−1, ko = 8.2× 10−10 sec−1, and kHO− = 0.19 M−l sec−1. The degradation rates are dependent on the side-chain substituents; it is predicted that sterically hindered MDP compounds will show an extended shelf life in aqueous solution. Product studies in the weakly acid pH region (where the pH of maximum stability occurs) show that MDP compounds degrade largely by hydrolysis of the dipeptide side chain. These data show that MDP 3 exhibits a shelf life (t90) of greater than 2 years in aqueous solutions of pH 4–4.5, the pH of maximum stability.

muramyldipeptide hydrolysis kinetics parenteral formulation high-pressure liquid chromatography (HPLC) 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    F. Ellouz, A. Adam, R. Ciobaru, and E. Lederer. Biochem. Biophys. Res. Commun. 59:1317–1325 (1974).Google Scholar
  2. 2.
    S. Kotani, Y. Watanabe, T. Shimono, T. Narita, K. Kato, D. E. S. Stewart-Tull, F. Kinoshita, K. Yokogawa, S. Kawata, T. Shiba, S. Kusumota, and Y. Tarumi. Z. Immun. Forsch. Exp. Ther. 149:302–319 (1975).Google Scholar
  3. 3.
    I. Azuma, K. Sugimura, Y. Yamamura, S. Kusumoto, Y. Tarumi, and T. Shiba. Jap. J. Microbiol. 20:63–66 (1976).Google Scholar
  4. 4.
    L. Chedid, C. Carelli, and F. Audibert. J. Reticuloendothel. Soc. 26(Suppl.):631–641 (1979).Google Scholar
  5. 5.
    E. B. Fraser-Smith, R. V. Waters, and T. R. Matthews. Infect. Immun. 35:105–110 (1982).Google Scholar
  6. 6.
    S. Kotani, Y. Watanabe, T. Shimono, K. Harada, T. Shiba, S. Kusumoto, K. Yokogawa, and M. Taniguchi. Bikeh J 19:9–13 (1976).Google Scholar
  7. 7.
    C. A. Dinarello, R. J. Elin, L. Chedid, and S. M. Wolff. J. Infect. Dis. 138:760–767 (1978).Google Scholar
  8. 8.
    E. E. Ribi, J. L. Cantreil, K. B. Von Eschen, and S. M. Schwartzman. Cancer Res. 39:4756–4759 (1979).Google Scholar
  9. 9.
    O. Kohashi, A. Tanaka, S. Kotani, T. Shiba, S. Kusumoto, K. Yokogawa, S. Kawata, and A. Ozawa. Infect. Immun. 20:70–75 (1980).Google Scholar
  10. 10.
    A. C. Allison, N. E. Byars, and R. V. Waters. In R. M. Nervig, P. M. Gough, M. L. Kaeberle, and C. A. Whetstone (eds.), Advances in Carriers and Adjuvants for Veterinary Biologics, Iowa State University Press, Ames, 1986.Google Scholar
  11. 11.
    A. C. Allison and N. E. Byars. J. Immunol. Methods 95:157–168 (1986).Google Scholar
  12. 12.
    N. E. Byars and A. C. Allison. Vaccine 5:223–228 (1987).Google Scholar
  13. 13.
    R. Hunter, F. Strickland, and F. Kezdy. J. Immunol. 127:1244–1250 (1981).Google Scholar
  14. 14.
    R. L. Hunter and B. Bennett. J. Immunol. 133:3167–3175 (1984).Google Scholar
  15. 15.
    R. L. Hunter and B. Bennett. Scand. J. Immunol. 23:287–300 (1986).Google Scholar
  16. 16.
    G. Jones, J. Moffat, and J. Nestor. U.S. Patent 4,082,735 (1978).Google Scholar
  17. 17.
    G. Jones, J. Moffat, and J. Nestor. U.S. Patent 4,082,736 (1978).Google Scholar
  18. 18.
    B. N. Jones and J. P. Gilligan. J. Chromatogr. 266:471–482 (1983).Google Scholar
  19. 19.
    R. S. Greelet. Anal. Chem. 32:1717–1718 (1960).Google Scholar
  20. 20.
    A. J. Kresge, H. J. Chen, G. L. Capen, and M. F. Powell. Can. J. Chem. 61:249–256 (1983).Google Scholar
  21. 21.
    T. W. Chan and A. R. Becker. Pharm. Res. 5:523–527 (1988).Google Scholar
  22. 22.
    L. Foster, D. Lidgate, N. Byars et al. (in preparation).Google Scholar
  23. 23.
    A. R. Becker et al. (in preparation).Google Scholar
  24. 24.
    P. R. Bevington. Data Reduction and Error Analysis for the Physical Sciences, McGraw-Hill, New York, 1969.Google Scholar
  25. 25.
    P. D. Bolton. Aust. J. Chem. 19:1013–1021 (1966).Google Scholar
  26. 26.
    D. M. Johnson, R. A. Pritchard, W. F. Taylor, D. Conley, G. Zuniga, and K. G. McGreevy. Int. J. Pharm. 31:125–129 (1986).Google Scholar

Copyright information

© Plenum Publishing Corporation 1988

Authors and Affiliations

  • Michael F. Powell
    • 1
    • 2
  • Linda C. Foster
    • 1
    • 3
  • Allyn R. Becker
    • 1
  • William Lee
    • 1
  1. 1.Institute of Pharmaceutical SciencesSyntex ResearchPalo Alto
  2. 2.Cytel CorporationSan Diego
  3. 3.California BiotechnologyMountain View

Personalised recommendations